PF 2400013

Drug Profile

PF 2400013

Alternative Names: PF-02400013; PF-2400013

Latest Information Update: 04 Mar 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Antipsychotics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Schizophrenia

Most Recent Events

  • 28 Feb 2011 Discontinued - Phase-I for Schizophrenia in USA (unspecified route)
  • 27 Sep 2010 Phase-I development is ongoing in USA
  • 27 Jan 2010 Phase-I clinical trials in Schizophrenia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top